<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853368</url>
  </required_header>
  <id_info>
    <org_study_id>M19-771</org_study_id>
    <secondary_id>2020-005805-25</secondary_id>
    <nct_id>NCT04853368</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis</brief_title>
  <official_title>A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and&#xD;
      digestive system, significantly impairing the quality of life, with those affected having a&#xD;
      median age of death at 40. The main objective of this study is to assess how safe and&#xD;
      effective is the combination therapy of galicaftor/navocaftor/ABBV-119 in adult participants&#xD;
      with CF who are homozygous or heterozygous for the F508del mutation in each arm.&#xD;
&#xD;
      Galicaftor/Navocaftor/ABBV-119 combination therapy is being developed as an investigational&#xD;
      drug for the treatment of CF. Study doctors place participants in 1 of the 4 groups, called&#xD;
      treatment arms. Each group receives a different treatment. Around 90 adult participants with&#xD;
      a diagnosis of CF will be enrolled in the study around approximately 35 sites worldwide.&#xD;
&#xD;
      Participants in arm 1 will receive oral capsules of galicaftor/navocaftor dual combination&#xD;
      for 28 days followed by galicaftor/navocaftor/ABBV-119 triple combination for 28 days.&#xD;
      Participants in arms 2 and 3 will receive the galicaftor/navocaftor/ABBV-119 triple&#xD;
      combination or placebo for 28 days. Participants in arm 4 will receive&#xD;
      galicaftor/navocaftor/ABBV-119 triple combination therapy for 28 days. For all study arms,&#xD;
      galicaftor, navocaftor, will be given once daily and ABBV-119 twice a day.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,&#xD;
      checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">October 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Percent predicted forced expiratory volume in 1 second (ppFEV1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Sweat Chloride (SwCl)</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Sweat chloride (SwCl) concentration is a biomarker of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Forced Vital Capacity [FVC]</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Forced vital capacity (FVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Forced Expiratory Flow at Mid-Lung Capacity [FEF25-75]</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Forced expiratory flow between 25% and 75% of exhaled volume (FEF25-75).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Changes From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Percent predicted forced expiratory volume in 1 second (ppFEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Changes From Baseline in Forced Vital Capacity [FVC]</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Forced vital capacity (FVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Changes From Baseline in Forced Expiratory Flow Between 25% and 75% of Exhaled Volume (FEF25-75)</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Forced expiratory flow between 25% and 75% of exhaled volume (FEF25-75).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>The CFQ-R is designed for use in participants with a diagnosis of cystic fibrosis and is designed to measure impact on overall health, daily life, perceived well-being, and symptoms. Participants will complete the CFQ-R electronically via a tablet device.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cystic Fibrosis (CF)</condition>
  <arm_group>
    <arm_group_label>F508del Homozygous Cystic Fibrosis (CF) Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508del homozygous cystic fibrosis (CF) participants receive galicaftor/navocaftor dual combination (28 days) followed by galicaftor/navocaftor/ABBV-119 triple combination therapy (28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F508del Heterozygous CF Participants (Active Drug Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508del heterozygous CF participants receive galicaftor/navocaftor/ABBV-119 combination therapy (28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F508del Heterozygous CF Participants (Placebo Group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508del heterozygous CF participants receive placebo (28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F508del Homozygous or Heterozygous CF Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508del homozygous or heterozygous CF participants receive galicaftor/navocaftor/ABBV-119 triple combination therapy for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galicaftor</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>F508del Heterozygous CF Participants (Active Drug Group)</arm_group_label>
    <arm_group_label>F508del Homozygous Cystic Fibrosis (CF) Participants</arm_group_label>
    <arm_group_label>F508del Homozygous or Heterozygous CF Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>F508del Heterozygous CF Participants (Placebo Group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navocaftor</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>F508del Heterozygous CF Participants (Active Drug Group)</arm_group_label>
    <arm_group_label>F508del Homozygous Cystic Fibrosis (CF) Participants</arm_group_label>
    <arm_group_label>F508del Homozygous or Heterozygous CF Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-119</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>F508del Heterozygous CF Participants (Active Drug Group)</arm_group_label>
    <arm_group_label>F508del Homozygous Cystic Fibrosis (CF) Participants</arm_group_label>
    <arm_group_label>F508del Homozygous or Heterozygous CF Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed clinical diagnosis of cystic fibrosis (CF).&#xD;
&#xD;
          -  Arm 1 participants with genotype homozygous for the F508del CF transmembrane&#xD;
             conductance regulator (CFTR) mutation and not receiving&#xD;
             elexacaftor/tezacaftor/ivacaftor (ETI) treatment .&#xD;
&#xD;
          -  Arm 2 and 3 participants with genotype heterozygous for the F508del CFTR mutation and&#xD;
             a minimal function and not receiving ETI treatment.&#xD;
&#xD;
          -  Arm 4 participants with genotype either homozygous or heterozygous for the F508del&#xD;
             mutation. Participants must be receiving stable (ETI) treatment.&#xD;
&#xD;
          -  Percent predicted forced expiratory volume in 1 second (ppFEV1) &gt;= 40% and &lt;=90% of&#xD;
             predicted normal for age, gender and height at screening.&#xD;
&#xD;
          -  For arms 1,2 and 3: sweat chloride (SwCl) &gt;= 60 mmol/L at screening. For participants&#xD;
             who participated in Study M19-530, it is acceptable to use a SwCl value that the&#xD;
             central lab provided in Study M19-530 to establish eligibility.&#xD;
&#xD;
          -  Weight &gt;= 35 kg at screening and Day -28 for arm 1 or day 1 for arms 2 to 4.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant laboratory values at screening that would pose undue risk for&#xD;
             the participant or interfere with safety assessments (per the investigator).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital /ID# 228781</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital /ID# 227281</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Limited /ID# 227279</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 228486</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital /ID# 227280</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Respiratory Health /ID# 227624</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uza /Id# 228533</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Brussel /ID# 226607</name>
      <address>
        <city>Jette</city>
        <state>Bruxelles-Capitale</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent /ID# 226605</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven /ID# 226608</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg /ID# 238499</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt /ID# 238497</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Essen - Ruhrlandklinik /ID# 238544</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln /ID# 238542</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena /ID# 238535</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover /ID# 238498</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orszagos Koranyi Pulmonologiai Intezet /ID# 228810</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum /ID# 234254</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum /ID# 234253</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis /ID# 234138</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenlane Clinical Centre /ID# 227282</name>
      <address>
        <city>Epsom</city>
        <state>Auckland</state>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital /ID# 227335</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 228044</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava Nemocnica Ruzinov /ID# 228041</name>
      <address>
        <city>Bratislava</city>
        <zip>821 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava Nemocnica Ruzinov /ID# 228042</name>
      <address>
        <city>Bratislava</city>
        <zip>821 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czechia</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis (CF)</keyword>
  <keyword>Galicaftor</keyword>
  <keyword>Navocaftor</keyword>
  <keyword>ABBV-119</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

